The stock of Quest Diagnostics Inc (NYSE:DGX) hit a new 52-week high and has $140.39 target or 61.00% above today’s $87.20 share price. The 9 months bullish chart indicates low risk for the $12.05B company. The 1-year high was reported on Nov, 21 by Barchart.com. If the $140.39 price target is reached, the company will be worth $7.35 billion more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 872,452 shares traded hands. Quest Diagnostics Inc (NYSE:DGX) has risen 15.02% since April 19, 2016 and is uptrending. It has outperformed by 11.16% the S&P500.
Quest Diagnostics Inc (NYSE:DGX) Ratings Coverage
Out of 9 analysts covering Quest Diagnostics (NYSE:DGX), 2 rate it a “Buy”, 1 “Sell”, while 6 “Hold”. This means 22% are positive. Quest Diagnostics has been the topic of 16 analyst reports since August 4, 2015 according to StockzIntelligence Inc. As per Monday, November 14, the company rating was upgraded by UBS. The stock has “Sell” rating given by Jyske Bank on Friday, June 24. The rating was initiated by Citigroup with “Neutral” on Friday, September 9. The stock of Quest Diagnostics Inc (NYSE:DGX) has “Sector Perform” rating given on Friday, January 29 by RBC Capital Markets. The stock has “Sector Perform” rating given by RBC Capital Markets on Friday, October 23. Zacks upgraded the stock to “Hold” rating in Tuesday, August 18 report. The rating was maintained by Mizuho on Friday, October 21 with “Neutral”. As per Wednesday, August 31, the company rating was downgraded by Mizuho. The rating was maintained by Canaccord Genuity with “Buy” on Friday, November 13. Mizuho maintained Quest Diagnostics Inc (NYSE:DGX) rating on Thursday, October 22. Mizuho has “Neutral” rating and $68 price target.
According to Zacks Investment Research, “Quest Diagnostics Inc., is the leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its national network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative new diagnostic tests and advanced healthcare information technology solutions that help improve patient care.”
Insitutional Activity: The institutional sentiment decreased to 0.92 in Q2 2016. Its down 0.15, from 1.07 in 2016Q1. The ratio dived, as 35 funds sold all Quest Diagnostics Inc shares owned while 173 reduced positions. 55 funds bought stakes while 168 increased positions. They now own 124.00 million shares or 7.05% less from 133.41 million shares in 2016Q1.
Vanguard Gru Inc holds 0.07% of its portfolio in Quest Diagnostics Inc (NYSE:DGX) for 12.91M shares. The United Kingdom-based Barclays Public Limited Company has invested 0.01% in Quest Diagnostics Inc (NYSE:DGX). Great West Life Assurance Co Can holds 0.18% or 698,642 shares in its portfolio. Marshall Wace Ltd Liability Partnership, a United Kingdom-based fund reported 595,601 shares. Eqis Capital Mgmt reported 11,187 shares or 0.06% of all its holdings. The Idaho-based Buffington Mohr Mcneal has invested 0.09% in Quest Diagnostics Inc (NYSE:DGX). Royal Bancshares Of Canada holds 243,342 shares or 0.01% of its portfolio. Homrich And Berg holds 6,273 shares or 0.05% of its portfolio. Private Advisor Group Llc accumulated 0.02% or 6,471 shares. Moreover, Piedmont Invest Advsrs Ltd Llc has 0% invested in Quest Diagnostics Inc (NYSE:DGX) for 57,830 shares. Advsr Asset Mngmt has invested 0.02% of its portfolio in Quest Diagnostics Inc (NYSE:DGX). Polaris Capital Limited Company has 1.96% invested in the company for 277,297 shares. Tompkins has 0.02% invested in the company for 722 shares. State Of Tennessee Treasury Department accumulated 31,677 shares or 0.01% of the stock. Mitchell Mcleod Pugh & Williams reported 2,480 shares or 0.18% of all its holdings.
Insider Transactions: Since July 25, 2016, the stock had 0 insider buys, and 5 insider sales for $4.94 million net activity. On Monday, July 25 ZIEGLER JOHN B sold $84,359 worth of the stock or 1,000 shares. 6,345 Quest Diagnostics Inc (NYSE:DGX) shares with value of $543,262 were sold by LEIDEN JEFFREY M. $340,808 worth of Quest Diagnostics Inc (NYSE:DGX) shares were sold by BRITELL JENNE K. $3.63 million worth of Quest Diagnostics Inc (NYSE:DGX) was sold by PFEIFFER GARY M.
More important recent Quest Diagnostics Inc (NYSE:DGX) news were published by: Forbes.com which released: “Ex-Dividend Reminder: Sanderson Farms, Quest Diagnostics and Agilent Technologies” on September 28, 2016, also Wsj.com published article titled: “Quest Diagnostics to Sell Focus Diagnostics to DiaSorin”, Wsj.com published: “UnitedHealth’s Optum Unit to Oversee Quest Diagnostics’ Billing Processes” on September 13, 2016. More interesting news about Quest Diagnostics Inc (NYSE:DGX) was released by: Wsj.com and their article: “Quest Diagnostics to Move Headquarters to Secaucus” with publication date: June 06, 2016.
DGX Company Profile
Quest Diagnostics Incorporated, incorporated on September 20, 1996, is a well-known provider of diagnostic information services. The Firm operates through two businesses: Diagnostic Information Services and Diagnostic Solutions.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.